November 15, 2011
The European Medicines Agency (EMA) announced on November 14 that Merck & Co. of the US has withdrawn its marketing authorization application (MAA) for Janacti (sitagliptin + pioglitazone), which was submitted in May this year. The product’s intended use was...read more